靶向肾脏的外泌体通过抑制miR-182-5p治疗肾缺血再灌注损伤

核心信息

• 论文英文标题: Renal-targeted exosomes inhibiting miR-182-5p for treatment of renal ischemia–reperfusion injury
• 期刊: Bioeng Transl Med
• 发表年份: 2025
• DOI: 10.1002/btm2.70081
• PMID/PMCID: 41573363; PMC12821224

研究概览

Utilizing bioinformatics approaches, the study further investigated and validated its downstream SIRT1/Nrf2 pathway, establishing its role in ferroptosis. The findings of our study demonstrated that miR-182-5p suppressed SIRT1/Nrf2 activity and facilitated ferroptosis, suggesting its potential as a therapeutic target for clinical IRI treatment.

核心发现

Renal ischemia-reperfusion injury (IRI) is a significant condition that leads to acute kidney injury, exacerbating the progression of renal failure clinically and affecting the patient's prognosis.

Following the identification of miR-182-5p as a significant molecule in IRI, we conducted a detailed analysis of its potential downstream genes and assessed its involvement in the SIRT1/Nrf2/ferroptosis pathway.

To validate these findings in vivo, we implemented an exosome-mediated drug delivery protocol and assessed its therapeutic efficacy in C57BL/6.

miR-182-5p exhibited a notable upregulation in renal IRI.

Echo Biotech 角色

293F外泌体+LTH靶向肽脂锚+exoload小核酸负载kit

关联平台: Echosome®, EV Materials / Reference Materials, Research Reagents & Tools

关联服务与能力: Small RNA / Cargo Loading, Targeting Peptide / Surface Modification, EV Material / Reference Material Supply

关联产品或试剂: ExoLoad® Nucleic Acid Loading Kit, ExoBrooch™ Targeting Peptide/Lipid Anchor Kit, Echo Biotech EV Material (brand/model to verify)

参考文献

原始论文: Renal-targeted exosomes inhibiting miR-182-5p for treatment of renal ischemia–reperfusion injury Bioengineering & Translational Medicine. 2025. DOI: 10.1002/btm2.70081. PMID/PMCID: 41573363; PMC12821224.